IAM
KERX

Integre Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Integre Asset Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-71,503
Closed -$534K – 186
2013
Q2 		$534K Buy
+71,503
New +$559K 0.14% 105

Other funds holding KERX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Integre Asset Management's KERX Position: Q3 2013 in Review

Integre Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2013, closing a stake of 71,503 shares — an estimated $534K sold.

Integre Asset Management first reported a position in KERX in Q2 2013 and held it in 1 quarter. The position peaked at $534K in Q2 2013. 110 funds tracked by Wall St. Rank hold KERX as of Q3 2013.

  • Integre Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2013 after selling out during the quarter.
  • Integre Asset Management sold 71,503 Keryx Biopharmaceuticals Inc shares in Q3 2013, an estimated $534K.
  • Integre Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 1 quarter.
  • Integre Asset Management's Keryx Biopharmaceuticals Inc position peaked at $534K in Q2 2013.
  • 110 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2013.

Based on Integre Asset Management's 13F filing for Q3 2013, filed 14 Nov 2013.